Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.
Eligibility Criteria
Inclusion Criteria: * Isolated hip fracture classified as AO/OTA 31A or 31B requiring surgical intervention. * Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation Exclusion Criteria: * Pathologic or periprosthetic hip fractures. * Fracture sustained \>24 hours before ED presentation. * Inter-hospital transfer. * Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia). * Use of a non-EMA-approved DOAC (e.g., betrixaban).